Lyme disease

2022 - 10 - 22

GlycoPath Inc. Applies Proprietary Technology to Lyme Disease to ... (BioSpace)

CHARLESTON, S.C., Oct. 21, 2022 /PRNewswire/ -- GlycoPath's proprietary GlycoTyper™ immunoaffinity technology was used to distinguish between Lyme disease ...

Earlier this year, results from the first GlycoFibroTyper™ study were published, showing that the GlycoFibroTyper™ assay was able to detect liver fibrosis and cirrhosis, the pre-malignant pre-cursor to hepatocellular carcinoma (HCC), with a higher sensitivity and specificity and overall accuracy than current standard of care. Mary Ann Comunale identified glycosylation changes that differentiate acute Lyme disease and track with treatment and partnered with GlycoPath to confirm her labs findings. 21, 2022 /PRNewswire/ -- GlycoPath's proprietary GlycoTyper™ immunoaffinity technology was used to distinguish between Lyme disease infection states and track treatment response through a collaboration with Drexel University College of Medicine, Philadelphia, PA.

Post cover
Image courtesy of "LymeDisease.org"

Pioneering Lyme Pediatrician Charles Ray Jones Dies at Age 93 (LymeDisease.org)

Dr. Charles Ray Jones, a trailblazing pediatric Lyme specialist who has treated more than 15000 children from around the world for tick-borne diseases, ...

Jones was harassed by the medical establishment for years. In addition to directly treating children for well over four decades, he helped countless more by training doctors and sharing his vast knowledge at conferences for both professionals and patients. Charles Ray Jones, 93, a trailblazing pediatric Lyme specialist who treated more than 15,000 children from around the world for tick-borne diseases, died on May 15, 2022, after a long illness.

Post cover
Image courtesy of "PRNewswire"

GlycoPath Inc. Applies Proprietary Technology to Lyme Disease to ... (PRNewswire)

PRNewswire/ -- GlycoPath's proprietary GlycoTyper™ immunoaffinity technology was used to distinguish between Lyme disease infection states and track ...

Earlier this year, results from the first GlycoFibroTyper™ study were published, showing that the GlycoFibroTyper™ assay was able to detect liver fibrosis and cirrhosis, the pre-malignant pre-cursor to hepatocellular carcinoma (HCC), with a higher sensitivity and specificity and overall accuracy than current standard of care. Furthermore, this assay is significantly less invasive, suitable for continuous monitoring, and provides a measurement of the overall health status of the liver. By utilizing the GlycoTyper™ methodology on a small cohort of patients, researchers were able to distinguish between control, acute and treated patients with a specificity of 94.7-100%. Mary Ann Comunale identified glycosylation changes that differentiate acute Lyme disease and track with treatment and partnered with GlycoPath to confirm her labs findings. Furthermore, they are unable to distinguish between newly infected patients and patients that have received prior treatment. 21, 2022 /PRNewswire/ -- GlycoPath's proprietary GlycoTyper™ immunoaffinity technology was used to distinguish between Lyme disease infection states and track treatment response through a collaboration with Drexel University College of Medicine, Philadelphia, PA.

Explore the last week